Yesterday, I published a long blog taking a first look at a 'treasure trove' of over 300 DOJ case summaries and some 300 actual full length court documents. Yesterday I focused on the 300 case summaries.
As often with DOJ press materials, adverse behavior is alleged and not convicted, with court cases underway.
###
The “reimbursable clinical fiction” is the core unit of fraud.
Medical necessity is the hinge, but scienter is the lock.
Certification is the bridge from regulatory violation to fraud.
Kickbacks are alleged as causation, not merely corruption.
Provider enrollment is a fraud chokepoint.
The cases separate nominal clinicians from economic architects.
Documentation is often alleged to be the crime scene.
Vulnerable patients are not incidental to the theory.
Program-design gaps become fraud opportunities.
Laundering and forfeiture convert billing cases into proceeds cases.
Civil, criminal, and administrative theories are increasingly braided.
The best defense themes arise from the same architecture as the prosecution themes.
###
Common Principles in the
DOJ Health Care Fraud Cases
The recent DOJ health care fraud pleadings are not merely a stack of unrelated indictments, informations, complaints, and settlements. Read together, they form a compact seminar in how modern health care fraud is alleged, structured, documented, and defended. The cases range across laboratories, pharmacies, wound care, hospice, durable medical equipment, behavioral health, controlled substances, and provider-enrollment schemes. Yet the recurring principles are strikingly consistent.
At the center is not simply a false bill. It is a false clinical premise converted into a reimbursable claim.
The government’s basic theory in case after case is that the defendant did not merely ask Medicare or Medicaid to pay too much. Rather, the claim allegedly represented that a qualifying medical event had occurred when, in the government’s view, the event was fabricated, distorted, induced, medically unnecessary, not documented, not performed, performed by the wrong person, or made possible by a kickback. The claim is the final electronic artifact. The alleged crime is the upstream manufacture of the medical reality that the claim purports to describe.
1. The “reimbursable clinical fiction” is the core unit of fraud.
The strongest unifying concept is the reimbursable clinical fiction. A hospice patient is represented as terminally ill. A laboratory test is represented as medically necessary and performed. A wound product is represented as clinically selected for an appropriate wound. A pharmacy claim is represented as a real prescription for a real patient need. A behavioral-health encounter is represented as a qualifying service provided by qualified personnel. A DME order is represented as physician-directed and beneficiary-needed.
The government’s theme is that these representations were not just incorrect; they were constructed. In the XXX laboratory case, the theory is that testing was routinely ordered without individualized medical judgment, sometimes not performed, and allegedly not used for diagnosis or treatment. In the XXX wound-care cases, the government’s theory is that sales and reimbursement incentives drove product selection rather than independent clinical judgment. In the XXX hospice case, eligibility documentation allegedly became a tool for converting non-qualifying or even impossible episodes into claims.
For prosecutors, this is a clean narrative: “They built paper medicine.” For defense counsel, the answer often begins by breaking apart that narrative: Was there an actual service? Was the service clinically arguable? Was any defect a billing failure, a documentation failure, or a knowing fraud? Did the defendant know the relevant facts at the time?
2. Medical necessity is the hinge, but scienter is the lock.
Medical necessity appears everywhere, but it does not carry the whole case by itself. In legitimate medicine, necessity is often probabilistic, contextual, and retrospective. A test may be low-yield but not fraudulent. A wound product may be expensive but not per se improper. A hospice prognosis may be uncertain. A behavioral-health service may be imperfect but still therapeutic.
The government therefore tends to make medical necessity persuasive by adding harder facts: no patient encounter, no specimen, no individualized assessment, blanket ordering, forged signatures, deceased patients, unqualified staff, impossible volumes, repeated high-dollar outliers, or records generated after the fact. In other words, the pleadings often use medical necessity as the doctrinal hinge, but objective evidence as the proof structure.
For defense lawyers, this distinction matters. A case built mainly on “that was unnecessary” is very different from one built on “there was no patient encounter, no specimen, no physician judgment, and the records were fabricated.” The former invites expert disagreement. The latter looks like fraud.
3. Certification is the bridge from regulatory violation to fraud.
The pleadings repeatedly emphasize enrollment forms, CMS-1500 forms, electronic claim submissions, EDI agreements, NPIs, CLIA-related obligations, provider participation agreements, and program manuals. This is not mere boilerplate. It is the legal bridge from operational misconduct to false claim.
A Medicare or Medicaid claim is treated as more than an invoice. It is a certified statement that the provider is eligible, the service was furnished as represented, the claim is accurate, and the service meets coverage conditions. The XXX laboratory FCA complaint makes this explicit: electronic claims certify medical necessity, truthfulness, accuracy, completeness, and the provider’s responsibility for claims submitted by its employees or agents. That certification architecture allows the government to argue that false clinical facts, false enrollment facts, and false compliance facts were material to payment.
For law professors, this is the jurisprudential heart of the modern FCA and health care fraud problem: when does regulatory noncompliance become payment fraud? These pleadings answer by stacking the elements. Not every violation is fraud. But a violation plus certification, plus materiality, plus payment, plus knowledge, plus concealment or remuneration, becomes the government’s preferred architecture.
4. Kickbacks are alleged as causation, not merely corruption.
The kickback allegations are especially important. They are not pled simply to show bad ethics. They are pled to explain causation.
In the XXX wound-allograft cases, kickbacks allegedly caused products to be ordered, patients to be found, providers to participate, and claims to be submitted. Sales representatives allegedly identified patients, selected or recommended product quantities, and received compensation tied to what could be billed. Providers allegedly became the credentialed conduit through which sales-driven care entered Medicare.
This matters because kickbacks solve a proof problem. Without kickbacks, a defendant may argue that the physician or clinician independently ordered the item. With kickbacks, the government argues that the medical judgment itself was corrupted before the claim was born. The kickback is thus not merely a separate Anti-Kickback Statute count; it becomes evidence that the resulting claims were false, tainted, and not the product of independent clinical decision-making.
For defense counsel, the counter-questions are equally important: Was the remuneration actually connected to referrals? Was it fair-market-value compensation for legitimate services? Did the clinician retain independent judgment? Did the defendant know the arrangement was unlawful? Was the claim false because of the remuneration, or was the government relying on guilt by association?
5. Provider enrollment is a fraud chokepoint.
Several cases show that provider enrollment is not administrative background. It is a fraud chokepoint.
The XXX reference-laboratory settlement is a compact example. The alleged misrepresentation was not that a particular lab result was wrong. It was that the provider-enrollment application concealed a relationship with another laboratory that was under suspension and investigation. The government’s theory is materiality at the threshold: had the relationship been disclosed, the program would not have enrolled the provider, and later claims would not have been payable.
This has broader implications. Health care fraud enforcement increasingly focuses on who gets access to the payment system in the first place. NPIs, ownership disclosures, managing-employee disclosures, related-party questions, prior suspensions, and nominee ownership structures are not clerical issues. They are gatekeeping representations. Falsehoods at the enrollment stage can make later claims suspect because the provider’s very right to bill was allegedly obtained by misrepresentation.
6. The cases separate nominal clinicians from economic architects.
A recurring feature is the distinction between the licensed person and the economic architect. The nominal clinician may be the prescriber, certifier, hospice physician, nurse practitioner, lab director, or ordering provider. But the alleged scheme is often designed by someone else: a marketer, owner, consultant, biller, sales representative, nominee owner, spouse, management company, or pass-through entity.
This distinction is central to both prosecution and defense. Prosecutors often argue that the person who designs the revenue machine “causes” the false claims, even if another person signs the order or submits the claim. Defense counsel may argue that causation is overextended: the billing company did not control medical judgment; the marketer did not submit the claim; the owner relied on professionals; the lab director did not know billing details; the clinician made an independent decision.
The cases therefore raise a common question: who is legally responsible for the final claim? The person who obtained the patient? The person who signed the order? The person who submitted the claim? The person who structured the kickback? The person who owned the entity? The government often answers: all of them, if they knowingly joined the mechanism that made the claim false.
7. Documentation is often alleged to be the crime scene.
In ordinary compliance, documentation is evidence of care. In these pleadings, documentation is often alleged to be the instrument of fraud.
The government repeatedly alleges false orders, forged signatures, backdated records, prefilled forms, cloned notes, false certifications, records generated after audits, false progress notes, and eligibility documents designed to pass program scrutiny. In the XXX hospice case, the alleged fraud turns heavily on patient status, certifications, identifiers, timing, and records. In the XXX laboratory and pharmacy cases, requisitions, prescriptions, orders, claims data, and audit responses become central evidence.
This is an important conceptual point. Health care fraud is rarely proven only by showing money moved. It is proven by comparing three records: the clinical record, the billing record, and the real-world patient event. The gap between those three is where the case lives.
8. Vulnerable patients are not incidental to the theory.
Several pleadings involve populations with reduced practical ability to detect, resist, or report exploitation: elderly Medicare beneficiaries, hospice patients, substance-use treatment patients, Medicaid beneficiaries, Native American fee-for-service Medicaid members, behavioral-health patients, and beneficiaries whose identities were used without meaningful consent.
This vulnerability does legal work. It helps explain why a scheme could scale. It supports the government’s narrative that the defendants selected populations less likely to challenge the claim event. It may influence detention, sentencing, restitution, and judicial perception. It also makes the cases more than financial fraud cases; they become abuse-of-trust cases.
For defense counsel, this creates a risk of moral overhang. Even where patient harm is not an element of the charged offense, the narrative of vulnerable beneficiaries can dominate the case. The defense must separate emotional gravity from statutory proof without appearing indifferent to patient welfare.
9. Program-design gaps become fraud opportunities.
The XXX pharmacy case is especially instructive because it shows how fraud allegations can arise from a policy transition. The alleged scheme exploited a temporary prior-authorization suspension for certain high-reimbursing drugs. The government’s theory is that defendants recognized a payment-system gap and flooded it with claims.
This category is likely to grow. Health care is full of temporary flexibilities, emergency policies, payment transitions, telehealth expansions, prior-authorization changes, new codes, and high-priced products. Fraud enforcement follows the gaps created by those transitions. The legal challenge is separating criminal exploitation from aggressive but facially permissible use of a changing rule.
That distinction should matter to both sides. A prosecutor will say: the defendants knew the clinical predicate was false, even if the payment window existed. A defense lawyer will say: the rule changed, the payment system accepted the claims, and the government is retrofitting criminal intent onto a messy administrative transition.
10. Laundering and forfeiture convert billing cases into proceeds cases.
The charging documents often do not stop at health care fraud. They add money laundering, monetary transactions in criminally derived property, seizure, forfeiture, substitute assets, and proceeds tracing. This is not incidental. It changes the litigation.
For prosecutors, proceeds allegations make the fraud tangible: real estate, vehicles, investment transfers, luxury goods, pass-through accounts, shell entities, foreign wires. These facts are narratively powerful because they show what the fraud allegedly bought. They also support asset restraint and potential recovery.
For defense counsel, proceeds counts create separate battlegrounds. Were the funds actually criminally derived? Was the transaction sufficiently connected to the specified unlawful activity? Did the money move before or after the alleged fraud was complete? Can the government trace the funds? Are legitimate revenues commingled? Does the forfeiture amount reflect gross proceeds, net proceeds, or loss?
11. Civil, criminal, and administrative theories are increasingly braided.
The cases show a continuum rather than a clean division. The same conduct can be framed as criminal health care fraud, conspiracy, kickbacks, money laundering, FCA false claims, reverse false claims, unjust enrichment, payment by mistake, provider-enrollment fraud, exclusion exposure, licensing misconduct, or controlled-substance violations.
For prosecutors, this allows strategic selection. The most egregious cases become criminal. Others resolve civilly. Some combine restitution, forfeiture, exclusion, and compliance consequences. For defense counsel, it means early characterization matters. A case may begin as an audit, become a suspension, become an FCA investigation, and later become a criminal matter if the government finds texts, emails, false records, kickbacks, or concealment.
The practical lesson is that health care fraud risk is not a single legal category. It is an ecosystem.
12. The best defense themes arise from the same architecture as the prosecution themes.
These cases also reveal the likely defense map. The principal defense issues are not mysterious. They are scienter, materiality, causation, medical necessity, reliance, delegation, loss, and regulatory ambiguity.
Scienter asks whether the defendant knew the claim was false, or merely operated in a confusing reimbursement environment. Materiality asks whether the misstatement actually mattered to payment. Causation asks whether the defendant caused the claim or was too remote from billing. Medical necessity asks whether the clinical judgment was fraudulent or merely debatable. Reliance asks whether the defendant reasonably relied on clinicians, billers, lawyers, consultants, or program guidance. Loss asks whether billed amounts, paid amounts, or medically worthless services are the correct measure. Regulatory ambiguity asks whether the government is criminalizing uncertainty.
The strongest government cases anticipate these defenses by alleging objective impossibilities, admissions, kickbacks, no services, fake records, or concealment. The weaker or more contestable cases are those that depend mainly on disagreement over clinical judgment or complex payment conditions.
Bottom Line
The common principle across these cases is that health care fraud is now charged as a systems crime. The alleged misconduct is not simply that someone lied on a claim form. It is that defendants allegedly learned the operating logic of Medicare, Medicaid, TRICARE, or another program, found the weak point, and converted clinical trust into reimbursable paper.
That is why these cases matter to prosecutors, defense attorneys, and law professors. They sit at the boundary between medicine, billing, administrative law, criminal law, and organizational design. The government’s best narrative is industrialized false medicine: patients, codes, forms, signatures, and program rules assembled into a revenue engine. The defense’s best response is precision: not every coverage violation is fraud, not every unnecessary service is criminal, not every payment error is material, and not every actor in the chain caused the false claim.
The serious legal work lies in that boundary.
###
###
CASE STUDY 01: MEDI-CAL PHARMACY, THE INDICTMENT AND THE DEFENSE
For #1, I’d pick the XXX Medi-Cal pharmacy complaint as the best defense-study example. It is factually serious, but analytically rich: it involves a temporary prior-authorization suspension, high-reimbursing non-contracted generic drugs, alleged sham prescriptions, alleged kickbacks, disputed medical necessity, causation through intermediaries, and the procedural posture of a criminal complaint supported by a probable-cause affidavit rather than a trial-tested record. The complaint alleges about $269 million in false claims and about $178 million paid, and it describes emails, beneficiary data, prescription forms, cooperator/witness statements, and approximately $279,000 allegedly paid to the XXX defendant.
A Defense-Strategy Case Study:
The XXX Medi-Cal Pharmacy Complaint
A particularly useful case to study from the defense perspective is the XXX Medi-Cal pharmacy complaint. As alleged, the defendant participated with others in a large pharmacy-billing scheme involving non-contracted generic drugs during a period when Medi-Cal had temporarily suspended prior authorization requirements as part of a pharmacy-benefit transition. The complaint alleges that prescriptions were generated for beneficiaries without real medical necessity, that some medications were not provided, that a pharmacy billed Medi-Cal for high-reimbursing drugs, and that the defendant received payments allegedly derived from the scheme. The case is especially interesting because it sits at the intersection of fraud, policy transition, medical necessity, kickbacks, causation, and the difference between aggressive exploitation of a payment window and criminal deception.
The defense should not begin by denying that the billing numbers look dramatic. They do. A better strategy is to force precision. The government’s narrative is “massive fraud following a prior-authorization suspension.” The defense should reframe the case around individual elements: What exactly did this defendant know? What exactly did this defendant do? Which specific prescriptions are charged or provable? Which medications were actually dispensed? Which patients were actually harmed? Which claims were false because of non-dispensing, which because of medical necessity, and which merely because the government now dislikes the economic effect of a temporary payment policy?
The first defense theme should be regulatory ambiguity and policy context. Medi-Cal temporarily suspended prior authorization for many prescription drugs during a program transition. That does not immunize fraud, but it matters greatly to scienter. The defense should argue that a fast-changing public program opened a legitimate billing pathway that Medi-Cal itself chose to create. The government will say the defendants exploited a safeguard failure. The defense should answer that exploiting an available coverage pathway is not itself fraud unless the government proves knowing falsity claim by claim. This is especially important if the charged conduct occurred in a confusing window when providers, pharmacies, prescribers, marketers, and intermediaries were all adjusting to new Medi-Cal Rx rules.
The second defense theme should be role separation. The defendant appears to be alleged as a facilitator or intermediary, not the pharmacy, not the state program, and not necessarily the licensed prescriber. The defense should isolate the defendant’s actual legal duty. Did the defendant submit claims? Did the defendant have direct access to the pharmacy’s billing system? Did the defendant control dispensing? Did the defendant make clinical determinations? Did the defendant know whether each beneficiary was seen, whether each medication was medically necessary, or whether each medication was dispensed? The government will try to collapse the chain into one conspiracy. The defense should pull it apart into separate actors: prescriber, pharmacy, marketer, billing entity, patient-contact person, and payer.
The third defense theme should be medical necessity as a contested clinical concept. The government’s strongest allegations are that prescriptions were generated without patient evaluation. But the defense should resist allowing “not medically necessary” to become a slogan. For each representative claim, the government should be forced to prove why the drug was unnecessary for that patient, what records existed, what diagnosis or complaint was documented, and what the prescriber understood. If the medication was facially within a prescriber’s authority and the patient had a plausible clinical indication, the defense can argue that the government is substituting retrospective skepticism for proof of fraud. The defendant’s non-clinician status, if applicable, strengthens this point: a non-clinical intermediary may not be able to adjudicate medical necessity.
The fourth defense theme should be causation and materiality. Medi-Cal paid the pharmacy, not the defendant. The defense should examine whether Medi-Cal would have denied payment if it knew the precise facts attributed to this defendant, as opposed to facts known only to the pharmacy or prescriber. If the prior-authorization requirement was suspended, the usual materiality story becomes more complex. The defense can argue that the alleged falsity must be tied to a condition of payment that remained operative during the suspension. The government may still prove falsity through lack of medical necessity, non-dispensing, or kickbacks, but it should not be allowed to imply that the mere absence of prior authorization was material when prior authorization had been suspended.
The fifth defense theme should be payments do not automatically equal kickbacks. The complaint alleges payments to the defendant, but the defense should characterize them, where possible, as consulting, administrative, marketing, patient-support, or business-development compensation unless the government proves unlawful remuneration tied to federal-health-care-program referrals. The defense should demand specificity: what service was supposedly bought, which referral was supposedly induced, what claim followed, and what evidence shows corrupt intent? If contracts, invoices, or business records exist, the defense should use them not as complete exoneration but as evidence that the relationship had at least a facial business form inconsistent with simplistic bribery.
The sixth defense theme should be attack the complaint posture. This is a complaint supported by an affidavit. It is a probable-cause document, not a conviction, not a tested indictment record, and not a set of facts found by a jury. The affidavit likely compresses witness statements, claims data, emails, bank records, and investigator interpretations into a single government narrative. The defense should stress that probable cause is a low threshold and that the case will depend on cross-examination, full context, document completeness, witness incentives, and claim-by-claim proof.
The seventh defense theme should be cooperator credibility and narrative contamination. If the government relies on pharmacy owners, prescribers, marketers, or other participants, the defense should assume those witnesses have powerful incentives to shift blame. A prescriber may say the defendant knew patients were not being seen; a pharmacy actor may say the defendant knew claims were false; a marketer may say payments were corrupt. The defense should test whether those statements are corroborated by contemporaneous documents or whether they are retrospective blame allocation by people with their own exposure.
The defense should also prepare for the government’s best facts. Emails attaching prescription forms, beneficiary lists, payment records, and alleged sham documentation will be hard to explain away if they are clear. The defense therefore should not overpromise innocence. A more credible strategy is to distinguish bad optics from criminal elements. It may be true that the business was aggressive, messy, highly profitable, and poorly supervised. The issue for trial is whether this defendant knowingly and willfully caused false claims to be submitted.
The ideal defense narrative is therefore: This case arose from a chaotic Medi-Cal policy transition. The state temporarily removed a payment safeguard. A pharmacy and licensed prescribers were responsible for dispensing, ordering, billing, and clinical judgment. The defendant was at most an intermediary in a business network and did not knowingly cause false claims. The government is using eye-popping dollar figures and the hindsight of an enforcement investigation to convert a complicated reimbursement environment into a simple fraud story.
That is not a guaranteed acquittal strategy. The alleged facts are serious. But it is the most intellectually coherent defense: narrow the defendant’s role, separate policy exploitation from criminal falsity, force claim-level proof, contest scienter, and prevent the prosecution from using the size of the scheme as a substitute for proof that this defendant knowingly caused false claims.
##
##
CASE STUDY 01: WOUND CARE, THE INDICTMENT AND THE DEFENSE
For #2, I’d use the XXX wound-allograft sales-executive indictment as the second strong defense-study case. It is useful because the government’s theory is sweeping — $1.2B billed, $614M paid, alleged kickbacks, sham invoices, pass-through accounts, vulnerable hospice patients, and personal proceeds — but the defense issues are also sophisticated: a sales executive versus treating clinicians, pricing versus kickbacks, Medicare reimbursement mechanics, causation, medical necessity, and proof of willful criminal intent. The DOJ summary says the defendant was charged by indictment with health care/wire fraud conspiracy, health care fraud, kickback conspiracy, paying kickbacks, and transactional money laundering.
A Second Defense-Strategy Case Study:
The XXX Wound-Allograft Sales-Executive Indictment
A second especially interesting case from a defense perspective is the XXX wound-allograft sales-executive indictment. As charged, the defendant was a senior sales executive for a company selling expensive amniotic wound allografts. The government alleges a large national scheme in which allografts were purchased, ordered, and billed through arrangements involving sales representatives, medical providers, alleged sham invoices, pass-through bank accounts, and kickbacks. According to the government’s theory, these financial incentives caused elderly Medicare patients, including some terminally ill or in hospice care, to receive medically unreasonable and unnecessary wound allografts, leading to approximately $1.2 billion in claims and about $614 million in payments.
This is a powerful prosecution narrative, but it is also a very instructive defense case because the defendant is not described as the bedside clinician, the treating physician, the nurse practitioner applying the graft, the Medicare-enrolled billing provider, or the person certifying medical necessity. He is alleged to be an economic and sales-side architect. That makes the defense problem different from the classic “doctor billed for services never rendered” case. The defense should not try to make the case sound small. It is not small. The better strategy is to separate commercial leadership from criminal causation.
The first defense theme should be role separation. The government will try to collapse the chain: sales executive, product distributor, sales representatives, providers, patients, claims, and payments all become one fraud machine. The defense should pull the chain apart. Who actually evaluated the wound? Who decided whether the allograft was medically necessary? Who applied it? Who documented the wound? Who selected the billing codes? Who submitted the Medicare claim? Who certified the claim was accurate? A sales executive may influence product sales, pricing, distributor strategy, and customer relationships, but those facts do not automatically prove that he knowingly caused a false medical claim.
The second defense theme should be medical necessity belongs first to clinicians. The government’s most emotionally powerful allegation is that vulnerable elderly patients, including hospice patients, received unnecessary allografts. The defense should not appear indifferent to that allegation. But it should insist that medical necessity is a patient-specific clinical judgment. Some wounds in elderly or medically complex patients may be difficult, chronic, recurrent, or clinically ambiguous. The fact that a patient was elderly, or even in hospice, does not by itself prove every wound-care intervention was fraudulent. The government should be required to prove, claim by claim or through statistically valid proof, that the allografts were unnecessary and that this sales executive knew they were unnecessary when the claims were submitted.
The third defense theme should be pricing and profit are not kickbacks by themselves. High product prices, aggressive sales incentives, rebates, discounts, and distributor margins may look ugly in hindsight, especially when Medicare reimbursement is large. But the defense should distinguish ordinary commercial economics from illegal remuneration. Was the alleged payment made to induce referrals or purchases reimbursable by federal programs? Or was it a discount, rebate, sales commission, consulting payment, distribution arrangement, or pricing structure with at least a facial business rationale? If invoices were inaccurate, were they intentionally sham documents designed to conceal kickbacks, or were they poorly structured commercial documents in a confusing reimbursement environment? The defense should force the government to prove corrupt purpose, not merely high margins.
The fourth defense theme should be causation is the hard element. The indictment theory, as summarized, appears to require that the executive’s conduct caused providers to submit false claims. That is a long causal chain. The defense should ask: Did the executive direct providers to bill Medicare? Did he know the providers’ actual acquisition cost? Did he instruct them what amounts to put on claims? Did he know what was in the patient charts? Did he know which patients were hospice patients? Did he know which wounds were infected, nonhealing, or unsuitable? Did he know any specific claim was false? The prosecution will use scale, emails, payment flows, and sales patterns to infer knowledge. The defense should answer with individualized proof problems: volume does not replace element-by-element causation.
The fifth defense theme should be attack the “sham invoice” label. The word “sham” is doing enormous work for the government. The defense should avoid accepting it. An invoice can be mistaken, incomplete, nonstandard, commercially aggressive, or even misleading without proving beyond a reasonable doubt that the defendant intended a federal health care fraud. The defense should examine whether invoice practices were reviewed by accountants, lawyers, reimbursement consultants, customers, or internal compliance personnel. If the providers themselves chose how to report acquisition cost or seek reimbursement, the defense should argue that responsibility for any billing representation rested with the billing provider, not the product seller.
The sixth defense theme should be separate Anti-Kickback Statute exposure from health care fraud exposure. The government will likely argue that kickback-tainted claims are false claims. The defense should still insist on precision. A possible AKS violation does not answer every question about health care fraud, wire fraud, intent, loss, or money laundering. If remuneration is disputed, the defense contests AKS. If remuneration is proven but medical necessity is disputed, the defense contests the scope of false claims. If claims were paid for products actually furnished, the defense contests loss. If the funds were ordinary business proceeds before any adjudication of fraud, the defense contests laundering and forfeiture theories.
The seventh defense theme should be use compliance ambiguity carefully. The defense should investigate whether the company had compliance materials, training, contracts, legal opinions, reimbursement guidance, fair-market-value analyses, or policies that the executive can point to. This is not a magic shield. But it can be powerful on willfulness. A sales executive who operated in a documented business structure, with lawyers or compliance personnel involved, is different from someone secretly paying cash in envelopes. The defense should look for evidence that the defendant believed the arrangements were lawful commercial relationships, not hidden inducements for federal program business.
The eighth defense theme should be humanize the business function without trivializing the conduct. A jury may dislike a defendant who made large sums while vulnerable patients were used in the scheme. The defense therefore must avoid sounding as if it is defending exploitation. The better narrative is narrower: this defendant sold a real wound-care product, through a commercial organization, to providers who had independent clinical and billing obligations. If some providers abused Medicare, or if some salespeople crossed lines, the question remains whether this defendant knowingly joined a criminal agreement to submit false claims.
The ninth defense theme should be contest loss and proceeds. The government’s large numbers will dominate the case unless narrowed. The defense should distinguish billed charges, allowed amounts, paid amounts, company revenue, gross product revenue, net profit, defendant compensation, and allegedly tainted transactions. If allografts were actually delivered and applied, the defense should challenge any loss theory that treats every dollar as worthless. If only a subset of claims is medically unsupported or kickback-tainted, the defense should resist extrapolation beyond reliable proof. On money laundering, the defense should test whether transactions involved criminally derived property, whether the defendant knew that, and whether the government can trace funds through business accounts.
The final defense narrative could be: This is a case about a high-dollar Medicare product market that the government now portrays as a fraud machine. But the defendant was a sales executive, not the treating clinician, not the Medicare billing provider, and not the person making patient-specific medical necessity decisions. The government must prove more than aggressive sales, high profits, and bad outcomes. It must prove beyond a reasonable doubt that this defendant knowingly caused false claims and knowingly paid unlawful remuneration, not merely that he participated in a lucrative and controversial wound-care business.
This is not an easy defense. The alleged facts are severe, and “sham invoices,” “pass-through accounts,” hospice patients, luxury purchases, and massive payments are all damaging themes. But as a defense case study, it is excellent because the best defense is not denial of scale. It is disciplined narrowing: role, knowledge, causation, clinical independence, lawful commercial structure, claim-level proof, and loss.
